218 related articles for article (PubMed ID: 32408060)
1. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
Talati C; Goldberg AD; Przespolewski A; Chan O; Ali NA; Kim J; Famulare C; Sallman D; Padron E; Kuykendall A; Lancet JE; Wang E; Tallman MS; Komrokji R; Sweet K
Leuk Res; 2020 Jun; 93():106367. PubMed ID: 32408060
[TBL] [Abstract][Full Text] [Related]
2. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
6. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Seiter K; Ahmed N; Shaikh A; Baskind P; Liu D
Leuk Res; 2016 Jul; 46():74-8. PubMed ID: 27151544
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
[TBL] [Abstract][Full Text] [Related]
8. Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
Zhang MY; Othus M; Shaw C; Schonhoff KG; Halpern AB; Appelbaum J; Hendrie PC; Walter RB; Estey EH; Percival MM
Leuk Lymphoma; 2023 May; 64(5):990-996. PubMed ID: 36891630
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
10. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
11. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
Vulaj V; Perissinotti AJ; Uebel JR; Nachar VR; Scappaticci GB; Crouch A; Bixby DL; Burke PW; Maillard I; Talpaz M; Marini BL
Leuk Res; 2018 Jul; 70():91-96. PubMed ID: 29908418
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.
Kanakasetty GB; R C; K C L; Dasappa L; Jacob LA; M C SB; K N L; Haleshappa RA; L K R; Saldanha SC; Deepak K; Rajesh P; Asati V
Ann Hematol; 2019 Apr; 98(4):881-888. PubMed ID: 30697642
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group.
Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Tantiworawit A; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1075-e1083. PubMed ID: 36117042
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
16. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
[TBL] [Abstract][Full Text] [Related]
17. The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.
Liu D; Wang X; Tong J; Zhou L; Chen E; Zhou Z; Xue L; Zhang X; Sun G; Zheng C
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676738
[No Abstract] [Full Text] [Related]
18. Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study.
Lessi F; Laurino M; Papayannidis C; Vitagliano O; Grimaldi F; Lazzarotto D; Gottardi M; Crisà E; Riva M; Reda G; Ermani M; Semenzato G; Trentin L; Ferrara F
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440176
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota VK
Leuk Res; 2019 Mar; 78():45-51. PubMed ID: 30716655
[TBL] [Abstract][Full Text] [Related]
20. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]